oligomeric amyloid beta mAb (Immunome)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameoligomeric amyloid beta mAb (Immunome)
Drug Alias NameN-huMABs program (Immunome)native human monoclonal antibodies therapy (Immunome)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmunome Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunome Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A